ProCE Banner Activity

CE / CME

A Game Changer for Follicular Lymphoma: Mastering Use of Precision Therapies as Part of a Chemo-Free Treatment Paradigm

Video

On-demand webcast of expert faculty presentation and case discussion on the evolving treatment landscape of follicular lymphoma, with particular attention paid to precision therapies as part of a chemo-free treatment approach.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Released: December 26, 2024

Expiration: June 25, 2025

Share

Faculty

Caron Jacobson

Caron Jacobson, MD

Associate Professor of Medicine
Harvard Medical School
Medical Director, Immune Effector Cell Therapy Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Peter Martin

Peter Martin, MD

Professor of Medicine
Weill Cornell Medicine
New York, New York

Sonali M. Smith

Sonali M. Smith, MD, FASCO

Elwood V. Jensen Professor of Medicine
Chief, Section of Hematology/Oncology
Co-Leader, Cancer Service Line
The University of Chicago
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC in partnership with Follicular Lymphoma Foundation.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca; Genmab US, Inc.; and Ipsen Biopharmaceuticals, Inc.

AstraZeneca

Genmab US, Inc.

Ipsen Biopharmaceuticals Inc

Partners

Follicular Lymphoma Foundation

ProCE Banner

Target Audience

This activity is intended for hematologists, oncologists, and other healthcare professionals who care for patients with relapsed/refractory follicular lymphoma.

Program Learning Goal

The goal of this activity is to improve learners’ knowledge, competence, and confidence to integrate new and emerging therapies into practice to improve clinical outcomes in patients with relapsed/refractory follicular lymphoma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the therapeutic rationale, as well as efficacy and safety evidence, for emerging therapies in the treatment of patients with relapsed/refractory follicular lymphoma

  • Apply clinical trial evidence, guidelines, and expert recommendations to optimize the selection and sequencing of bispecific antibodies, CAR T-cell therapy, and epigenetic modifiers for patients with relapsed/refractory follicular lymphoma

  • Mitigate and manage adverse events associated with novel treatment regimens in relapsed/refractory follicular lymphoma according to guidelines and expert recommendations

  • Assess patients for equitable enrollment on clinical trials of BTK inhibitors and other novel therapies and combinations for relapsed/refractory follicular lymphoma

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Sonali M. Smith, MD, FASCO

Elwood V. Jensen Professor of Medicine
Chief, Section of Hematology/Oncology
Co-Leader, Cancer Service Line
The University of Chicago
Chicago, Illinois

Sonali M. Smith, MD, FASCO: consultant/advisor/speaker: Genmab, Ono, Regeneron.

Primary Author

Caron Jacobson, MD

Associate Professor of Medicine
Harvard Medical School
Medical Director, Immune Effector Cell Therapy Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Caron Jacobson, MD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, Appia, AstraZeneca, Bristol Myers Squibb, Caribou, Galapagos, Janssen, Kite/Gilead, Kyverna, Miltenyi, Novartis, Sana, Synthekine.

Peter Martin, MD

Professor of Medicine
Weill Cornell Medicine
New York, New York

Peter Martin, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, Genentech, Janssen, Merck, PeproMene.

The planners and content peer reviewers from Clinical Care Options, LLC and Follicular Lymphoma Foundation do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 26, 2024, through June 25, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification 

A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.